2025-04-08 17:39:13
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Sun Pharmaceutical Industries Ltd consolidated Q2FY23 PAT higher at Rs. 2260.17 crores
Posted On : 2022-11-01 16:06:47( TIMEZONE : IST )
Sun Pharmaceutical Industries Limited has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 11037.5 crores during the period ended September 30, 2022 as compared to Rs. 10763.90 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 2260.17 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 2095.85 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 9.4 for the period ended September 30, 2022 as compared to Rs. 8.6 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 11037.5 crs | ₹10763.90 crs |  2.54% |
| Net Profit | ₹2260.17 crs | ₹2095.85 crs | 7.84% |
| EPS | ₹9.4 | ₹8.6 | 9.30% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 11037.5 crores during the period ended September 30, 2022 as compared to Rs.9848.82 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.2260.17 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.2088.73 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.9.4 for the period ended September 30, 2022 as compared to Rs.8.5 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 11037.5 crs | ₹9848.82 crs | 12.07% |
| Net Profit | ₹2260.17 crs | ₹2088.73 crs | 8.21% |
| EPS | ₹9.4 | ₹8.5 | 10.59% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.21801.40 crores during the 6 Months period ended September 30, 2022 as compared to Rs.19720.08 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.4356.02 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.3497.38 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.18 for the 6 Months period ended September 30, 2022 as compared to Rs.14.5 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹21801.40 crs | ₹19720.08 crs | 10.55% |
| Net Profit | ₹4356.02 crs | ₹3497.38 crs | 24.55% |
| EPS | ₹18 | ₹14.5 | 24.14% |
Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1015.95 as compared to the previous close of Rs. 989.75. The total number of shares traded during the day was 212946 in over 6080 trades.
The stock hit an intraday high of Rs. 1027.10 and intraday low of 990.00. The net turnover during the day was Rs. 216566392.00.
